PrECOG Cancer Research Group

Encouraging results for the treatment of mantle cell lymphoma from PrECOG today. The phase 2 trial PrE0405 met its primary endpoint. "With a median age of 60 to 70 years at diagnosis, many patients with mantle cell lymphoma are ineligible for aggressive treatments," said Dr. Craig Portell, who led the study. "In PrE0405, we observed an 85% complete response rate from a lower-intensity therapy." The American Society of Hematology 2023 annual meeting featured the data. #ASH23 https://ow.ly/tsOS50QhzV1

ECOG-ACRIN Group Co-Chairs congratulate Dr. Monica Bertagnolli on her appointment as Director of the National Institutes of Health: We are pleased by the Senate’s confirmation today of Dr. Monica Bertagnolli as Director of the National Institutes of Health (NIH), and we are excited at the prospect of continuing to collaborate with our friend and colleague in her new role. Dr. Bertagnolli is well known for her commitment to the entire research continuum from basic to clinical science and her focus on improving outcomes for patients. Her appointment will facilitate and support key objectives advancing medical research across the spectrum. Congratulations Dr. Bertagnolli! We’re confident in our shared values as they pertain to the advancement of medical research and look forward to the continued collaboration between the ECOG-ACRIN Cancer Research Group and NIH. Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD Group Co-Chairs ECOG-ACRIN Cancer Research Group https://lnkd.in/gpbefwJx